2cureX Newsletter. Our colorectal cancer portfolio is on track – Pancreatic cancer is next.

June 15 | 2023

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, has today issued a newsletter that can be accessed via the attachment with this message.

We regularly publish such newsletters compiling recent events and news that can be of interest to our subscribers and followers.